---
title: "Melanotan II"
canonical_url: https://peptidelibrary.app/library/melanotan-ii
description: "Cyclic α-MSH analog used illicitly for tanning and libido. Not FDA-approved. FDA and EMA have warned against its use. WADA S0 as a non-approved substance."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Melanotan II

Melanotan II (also called MT-II or Melanotan 2) is an unapproved melanocortin agonist. Melanotan II is a cyclic lactam analog of alpha-melanocyte-stimulating hormone and a non-selective agonist across melanocortin receptors, engaging MC1R, MC3R, MC4R and MC5R. MC1R activation on melanocytes drives eumelanin synthesis independently of ultraviolet exposure.

Cyclic α-MSH analog used illicitly for tanning and libido. Not FDA-approved. FDA and EMA have warned against its use. WADA S0 as a non-approved substance.

Also known as: MT-II, Melanotan 2.

Categories: Cosmetic, Experimental.

## Classification

- Type: Unapproved melanocortin agonist
- Mechanism class: Melanocortin receptor agonist
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Melanotan II is a cyclic lactam analog of alpha-melanocyte-stimulating hormone and a non-selective agonist across melanocortin receptors, engaging MC1R, MC3R, MC4R and MC5R. MC1R activation on melanocytes drives eumelanin synthesis independently of ultraviolet exposure. MC4R activation in the hypothalamus accounts for the appetite suppression and, through spinal and central pathways, the sexual arousal effects reported with it — the observation that led to the development of bremelanotide, which was derived from it. That lack of receptor selectivity is the source of its side-effect profile, including nausea, flushing and darkening of existing naevi. It is not approved anywhere and is sold only as a research chemical.

Targets: MC1R, MC4R, MC3R.

Origin: Synthetic cyclic lactam α-MSH analog.

## Properties

- Molecular formula: C50H69N15O9
- Molecular weight: 1,024.2 g/mol
- CAS number: 121062-08-6
- Half-life: Not established in humans (no published human pharmacokinetic study)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 2
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 1998

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996. 1996. Controlled human trial. Population: Normal male volunteers (n=3). Safety and erectile response [Source](https://pubmed.ncbi.nlm.nih.gov/8637402/)
2. Wessells H et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998. 1998. Human study (early or uncontrolled). Population: Men with psychogenic erectile dysfunction. Erectile response [Source](https://pubmed.ncbi.nlm.nih.gov/9679884/)
3. NCT07437560 — Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation. Human study (early or uncontrolled). Population: Patients with vitiligo (planned n=60). Repigmentation as an adjunct to NB-UVB phototherapy. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT07437560)

### Registered trials

- [NCT07437560](https://clinicaltrials.gov/study/NCT07437560)

## Safety

Side effects: Nausea; Flushing; Spontaneous erections; New moles; Hypertension.

Risks: Unapproved tanning peptide; WADA S0; Mole and blood-pressure risks.

Contraindications: Avoid if prone to moles; Not recommended with heart conditions.

Human safety basis: Limited human reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Melanotan II is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Melanotan II?

Cyclic α-MSH analog used illicitly for tanning and libido. Not FDA-approved. FDA and EMA have warned against its use. WADA S0 as a non-approved substance.

### How does Melanotan II work?

Melanotan II is a cyclic lactam analog of alpha-melanocyte-stimulating hormone and a non-selective agonist across melanocortin receptors, engaging MC1R, MC3R, MC4R and MC5R. MC1R activation on melanocytes drives eumelanin synthesis independently of ultraviolet exposure.

### Is Melanotan II FDA approved?

No. Melanotan II is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A nomination: Previously in Category 2; nomination withdrawn by the nominators.

### What is the half-life of Melanotan II?

No human half-life has been published for Melanotan II. The pharmacokinetic studies indexed in PubMed were in rats and mice, where it cleared rapidly from plasma. Figures quoted by vendors and forums have no published human study behind them.

### Is Melanotan II banned in sport?

Melanotan II is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Melanotan II?

Compounds most often compared with Melanotan II include Afamelanotide, Bremelanotide, Setmelanotide and KPV. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II — Chemistry, 2024](https://pubmed.ncbi.nlm.nih.gov/38285527/)
- [Melanotan-II reverses memory impairment induced by a short-term HF diet — Biomed Pharmacother, 2023](https://pubmed.ncbi.nlm.nih.gov/37478579/)
- [CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists — J Med Chem, 2022](https://pubmed.ncbi.nlm.nih.gov/35188390/)
- [Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice — Exp Physiol, 2021](https://pubmed.ncbi.nlm.nih.gov/33332767/)
- [Melanotan II User Experience: A Qualitative Study of Online Discussion Forums — Dermatology, 2021](https://pubmed.ncbi.nlm.nih.gov/34464955/)
